Valuation: Nexstim Oyj

Market Cap 7.76Cr 8.84Cr 7.23Cr 6.65Cr 12Cr 844.75Cr 13Cr 86Cr 34Cr 418.94Cr 33Cr 32Cr 1.45TCr P/E 2026 *
80.1x
P/E 2027 * 35.6x
Enterprise Value 7.55Cr 8.6Cr 7.03Cr 6.47Cr 12Cr 821.89Cr 12Cr 83Cr 33Cr 407.6Cr 32Cr 32Cr 1.41TCr EV / Sales 2026 *
5.94x
EV / Sales 2027 * 4.59x
Free-Float
58.2%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 49 11/02/2020
Director of Finance/CFO 40 11/02/2020
Chief Tech/Sci/R&D Officer 65 01/01/2008
Director TitleAgeSince
Director/Board Member 64 11/11/2019
Chairman 63 11/11/2019
Director/Board Member 55 01/05/2021
Change 5-day change 1-year change 3-year change Capi.($)
-6.90%-5.73% - - 8.84Cr
+3.02%+10.12%+18.86%+2.59% 21TCr
+1.30%+11.19%-1.92%-23.46% 14TCr
+1.39%+3.35%-26.75%+10.80% 13TCr
+1.21%+6.65%-56.48%-10.89% 6.85TCr
+0.77%-1.03%+6.61%-0.07% 4.82TCr
+0.13%+4.43%-25.61%-31.65% 4.56TCr
+1.92%+5.78%+17.57%+11.50% 3.97TCr
+3.42%+4.45%+26.97%+34.34% 3.77TCr
+2.90%+6.72%-23.60%-6.37% 3.01TCr
Average +0.92%+4.52%-7.15%-1.47% 8.35TCr
Weighted average by Cap. +1.89%+5.29%-4.47%-2.63%

Financials

2026 *2027 *
Net sales 1.27Cr 1.45Cr 1.18Cr 1.09Cr 2.04Cr 138.25Cr 2.07Cr 14Cr 5.49Cr 69Cr 5.43Cr 5.32Cr 236.89Cr 1.61Cr 1.83Cr 1.5Cr 1.38Cr 2.58Cr 175.27Cr 2.63Cr 18Cr 6.96Cr 87Cr 6.89Cr 6.74Cr 300.31Cr
Net income 10L 11.39L 9L 9L 16.06L 11Cr 16.33L 1.1Cr 43.24L 5.4Cr 42.78L 41.85L 19Cr 22L 25.07L 20.49L 18.84L 35.32L 24Cr 35.93L 2.43Cr 95.13L 12Cr 94.11L 92.08L 41Cr
Net Debt -21L -23.93L -19.56L -17.99L -33.72L -23Cr -34.29L -2.32Cr -90.81L -11Cr -89.83L -87.89L -39Cr -37L -42.16L -34.45L -31.69L -59.41L -40Cr -60.42L -4.09Cr -1.6Cr -20Cr -1.58Cr -1.55Cr -69Cr
Logo Nexstim Oyj
Nexstim Oyj is a Finland-based medical technology company. It is focused on improving rehabilitation for stroke patients through the use of noninvasive brain stimulation. Its offering comprises: a diagnostic tool for brain surgery planning, Navigated Brain Stimulation (NBS) System, which comprises navigated transcranial magnetic stimulation (nTMS) device for presurgical mapping (PSM) of the motor and speech cortices; and a device for stroke therapy called Navigated Brain Therapy (NBT) System, which focuses stimulation on targeted locations in the brain in order to enhance rehabilitation process. The NBT System targets upper limb motor disability and is under Phase III pivotal clinical trial study at rehabilitation sites in the United States. The Company’s systems are used in over 100 facilities in research, therapy and neurosurgical planning purposes. Nexstim Oyj has two subsidiaries: Nexstim Inc and Nexstim Germany GmbH.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-